
Roche cuts ties with Inovio in hepatitis B development
pharmafile | August 3, 2016 | News story | Research and Development | Inovio, Roche, hepatitis B
Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued notice that it would cease its licensing collaboration on the drug.
Roche only paid $10 million upfront to co-develop some of Inovio’s early stage pipeline assets, including, INO-1800 but the deal was worth a potential $422 million through milestone payments.
All rights granted to Roche related to INO-1800, including the right to license the product to other parties, will now be returned to Inovio. The company has signalled their intent to continue its current Phase I study of INO-1800, with enrolment anticipated in Q1 2017, and results expected in Q2 later that year.
CEO Dr Joseph Kim says: “While we acknowledge Roche’s strategic decision in the area of hepatitis B, we are optimistic that our potent immunotherapy platform will make a difference in this globally important chronic viral infection, similar to what we have demonstrated in HPV-related disease. Inovio was already managing the Phase I clinical trial so the study will continue on track without disruption.”
Investors didn’t share Kim’s optimism, with share sat Inovio falling 6% at the time of writing.
Sean Murray
Related Content

Roche secures CE Mark for automated latent tuberculosis blood test
Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …

Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory
Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance …

Global study calls for overhaul of hepatitis B care to meet WHO targets
A major global study has warned that current models of hepatitis B care are failing …





